European Society of Cardiology

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Retrieved on: 
Monday, February 26, 2024
Sengupta, HSCS, Rutgers University, Division, AI, Intelligence, Cardiac imaging, Education, Teaching, Echocardiography, University School, Editor-in-chief, ECG, American Medical Association, Society, Heart failure, Lung, TEDMED, European Society of Cardiology, Journal, FACC, MBBS, Publication, Holography, Research, Medical device

Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.

Key Points: 
  • Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
  • He served on the Board of Directors for the American Society of Echocardiography (ASE) and as the Chair of the ASE Telehealth and New Technology Taskforce.
  • In 2020, Dr. Sengupta was named a Richard Popp Excellence in Teaching Award recipient by the American Society of Echocardiography.
  • I look forward to helping HeartSciences further advance the field of AI in cardiology.”

Multi Board-Certified Physician Sam Setareh Opens MDVIP-Affiliated Primary Care Practice in Los Angeles

Retrieved on: 
Wednesday, February 14, 2024
Pharmacy, Cedars-Sinai Medical Center, American Heart Association, LOS, Suite, Molina Healthcare, Physician, Mount Sinai West, AHA, Cardiovascular disease, Cardiovascular technologist, MDVIP, ESC, Heart failure, Textbook, Health, University, Innovation, Medicare, Internal medicine, American College, Executive, Patient, Journal, European Society of Cardiology, Public key certificate, ACC, Athlete, Partnership

LOS ANGELES and BOCA RATON, Fla., Feb. 14, 2024 /PRNewswire/ -- MDVIP, the market leader in personalized healthcare with a network of over 1,100 physicians nationwide, today announced the opening of a new MDVIP-affiliated internal medicine practice in Los Angeles. Sam Setareh, M.D., M.S., F.A.C.C., is currently accepting patients who want a more direct relationship with their primary care physician. Dr. Setareh brings an impressive and diversified background to MDVIP, including four board certifications in Internal Medicine, Cardiovascular Disease, Nuclear Cardiology and Echocardiology, and he is an attending physician at Cedars-Sinai Medical Center in Los Angeles.  Dr. Setareh serves as a member of multiple committees on the American College of Cardiology and the American Heart Association and as a founding member of the editorial board of The Journal of Scientific Innovation in Medicine.

Key Points: 
  • , is currently accepting patients who want a more direct relationship with their primary care physician.
  • Dr. Setareh brings an impressive and diversified background to MDVIP, including four board certifications in Internal Medicine, Cardiovascular Disease, Nuclear Cardiology and Echocardiology, and he is an attending physician at Cedars-Sinai Medical Center in Los Angeles.
  • "As an MDVIP-affiliated primary care physician, my mission is to help empower patients to take better control of their health through preventive medicine and highly individualized care," said Dr. Setareh, who has subspecialties in preventive cardiology, sports cardiology and advanced cardiovascular imaging.
  • He has treated and taken care of patients from all walks of life, including the most vulnerable to heads-of-state, dignitaries, athletes, celebrities and physician colleagues.

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

Retrieved on: 
Wednesday, January 17, 2024
Mortality, Death, Patient, Incidence, ICU, Cytokine adsorbing column, Vasoplegic syndrome, Semmelweis University, Professional corporation, DRS, European Society of Cardiology, RCT, Heart, Standard of care, Pelvic floor dysfunction, Cytosorbents Corporation, Circulatory system, Risk, Organ dysfunction, VS, Multiple organ dysfunction syndrome, Observational study, Shock, Randomized controlled trial, ESC, Dentistry

In particular, vasoplegic syndrome (VS), a form of circulatory failure or shock, is routinely seen in these patients and can cause worsened organ failure.

Key Points: 
  • In particular, vasoplegic syndrome (VS), a form of circulatory failure or shock, is routinely seen in these patients and can cause worsened organ failure.
  • In a prior observational study , CytoSorb was associated with the reduced severity of vasoplegia in heart transplant patients, in addition to other clinical benefits.
  • In this prospective, single-center, open-label RCT, 60 heart transplant recipients were randomly assigned to either receive intraoperative CytoSorb hemoadsorption or standard of care.
  • Now, Nemeth, Soltesz, and colleagues have confirmed many of these observations in this rigorous and well-designed groundbreaking randomized controlled trial in orthotopic heart transplant patients.

LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
ESC, Bristol Myers Squibb, JAMA Cardiology, LIBRA, MITES, Clinical trial, Patient, Demodex, BMS, Congress, European Society of Cardiology, Pharmaceutical industry, Cardiology, Hong Kong

Under the terms of the agreement, LianBio is entitled to receive a total consideration of $350 million.

Key Points: 
  • Under the terms of the agreement, LianBio is entitled to receive a total consideration of $350 million.
  • In July 2023, LianBio entered into a clinical supply agreement with AstraZeneca in China to procure osimertinib for this clinical trial.
  • In October 2023, LianBio announced that the company’s Board of Directors initiated a comprehensive strategic review of the company, with an update anticipated in the first half of 2024.
  • Cash, cash equivalents, marketable securities and restricted cash at September 30, 2023 totaled $252.2 million compared to $302.4 million as of December 31, 2022.

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Retrieved on: 
Sunday, November 12, 2023
NDA, Medicine, PALO, ACM, Safety, Food, Month, Cardiology, European Society of Cardiology, CVH, AHA, Mortality, Patient, ATTR, FDA, American Heart Association, Survival, Cancer, TTR, Medical school, DSM-IV codes, Pharmaceutical industry

PALO ALTO, Calif., Nov. 12, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented additional Phase 3 data from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, at the American Heart Association (AHA) Scientific Sessions 2023. ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR). In July, BridgeBio announced positive topline results from ATTRibute-CM, and in August, BridgeBio presented detailed positive results at the European Society of Cardiology Congress 2023. BridgeBio will host an investor call on Sunday, November 12 at 11:15 am ET to discuss these results.

Key Points: 
  • ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR).
  • In July, BridgeBio announced positive topline results from ATTRibute-CM, and in August, BridgeBio presented detailed positive results at the European Society of Cardiology Congress 2023.
  • BridgeBio will host an investor call on Sunday, November 12 at 11:15 am ET to discuss these results.
  • “The positive results of the ATTRibute-CM study demonstrate that acoramidis improved clinical outcomes for ATTR-CM patients, even in the contemporary care setting.

iFR and FFR are equally safe to diagnose and treat heart disease according to largest-ever analysis of new real-world, long-term data

Retrieved on: 
Thursday, October 26, 2023
Clinical Science (journal), Gold standard, European Society of Cardiology, AEX, Public sector banks in India, American College, Interventions, NYSE, INT, PHG, Pilot in command, ESC, Pressure, Lund University, Safety, Revascularization, American Heart Association, JACC, Risk, Guideline, MACE, PCI, Blood, FFR, TCT, Patient, Diagnosis, Death, EACTS, American College of Cardiology, Medical device, Pharmaceutical industry, Medical imaging, Cardiology

iFR is an innovative pressure-derived index only offered by Philips that is used to assess coronary blockages during interventional procedures.

Key Points: 
  • iFR is an innovative pressure-derived index only offered by Philips that is used to assess coronary blockages during interventional procedures.
  • The analysis, “Long-term Safety of Revascularization Deferral Based on Instantaneous Wave-Free Ratio or Fractional Reserve,” compares patient outcomes using iFR and FFR in the diagnosis and treatment of heart disease.
  • The cumulative MACE risks for each group differentiated by 1.6% (iFR: 21.5%, FFR: 19.9%, HR 1.09 (95% CI: 0.90-1.33 at 5 years).
  • iFR is considered the Gold Standard for hyperemia-free physiologic assessment for measuring pressure in diagnostic and interventional procedures [1,4].

New Study Published in Cardiovascular Digital Health Journal Shows Implicity's Algorithm Significantly Reduces AF Alert Burden in Remote Cardiac Monitoring

Retrieved on: 
Tuesday, October 24, 2023
RPM, Stroke, National Association Medical Staff Services, European Heart Journal, Trial of the century, Incidence, MMSc, ESC, Physician, Atrial fibrillation, Arrhythmia, European Society of Cardiology, Doctor of Philosophy, Classification, AF, CI-966, Patient, Medtronic, Heart failure, Fatigue, Medical device, Nursing, MD, Cardiology, Implication (information science)

CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Implicity, a leader in remote patient monitoring (RPM) and cardiac data management solutions, today announced the results of a clinical study published in the Cardiovascular Digital Health Journal.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Implicity , a leader in remote patient monitoring (RPM) and cardiac data management solutions, today announced the results of a clinical study published in the Cardiovascular Digital Health Journal.
  • "For a patient with AF who is already anticoagulated, a single AF episode isn't as important as established patterns or occurrences associated with arrhythmia progression and patient outcomes.
  • Results showed the algorithm broke down 67,883 AF burden-related alerts into 9,728 (14.3%) clinically relevant AF events, according to the European Society of Cardiology classification.
  • Implicity's algorithm works with any device that collects atrial burden trends data and can classify the following scenarios in line with ESC recommendations:

SpectraWAVE Secures 510(k) Clearance to Add Saline Imaging and Expanded Artificial Intelligence Features to the HyperVue™ Imaging System

Retrieved on: 
Tuesday, September 19, 2023
Technology, Medical Devices, Medical Supplies, FDA, Health Technology, Cardiology, Hardware, Health, Artificial Intelligence, Plaque, Blood vessel, Myocardial infarction, EEL, Fractional flow reserve, Food and Drug Administration, NIRS, CAD, Nasiriyah Heart Center, Intelligence, Multimedia, Angiography, Meta-analysis, Calcium, Congress, Acquisition, Patient, Physician, Risk, Algorithm, Artificial intelligence, St. Francis Hospital, Coronary artery disease, European Society of Cardiology, Arrest, Food, Medical imaging

The intravascular imaging system combines next-generation DeepOCT™ images and near infrared spectroscopy (NIRS) with state-of-the-art ease of use to support physicians optimizing coronary stenting in the cardiac catheterization lab.

Key Points: 
  • The intravascular imaging system combines next-generation DeepOCT™ images and near infrared spectroscopy (NIRS) with state-of-the-art ease of use to support physicians optimizing coronary stenting in the cardiac catheterization lab.
  • Newly cleared product enhancements include contrast-free saline imaging, artificial intelligence algorithms to support the identification of key clinical structures of calcium and external elastic lamina (EEL), and hands-free angiographic co-registration.
  • The latest clearance adds to the existing HyperVue toolkit , which includes artificial intelligence enabled lipid, lumen, stent, and sidebranch detection, as well as the no-flush prep Starlight™ Imaging Catheter designed for efficient setup and image acquisition in complex lesions.
  • Next generation DeepOCT and Near Infrared Spectroscopy intravascular imaging system now includes compatibility with contrast-free saline imaging, advanced artificial intelligence algorithms to identify calcium and external elastic lamina, and hands-free angiographic co-registration.

Shockwave Medical Appoints Nick West as Associate Chief Medical Officer

Retrieved on: 
Tuesday, September 12, 2023
Green Lane Hospital, Plaque, FRCP, University, Shock wave, Charing Cross Hospital Medical School, UCLA School of Nursing, Trinity Hall, University of Cambridge, FACC, Cardiovascular disease, Medicine, CMO, Associate, IVL, Congress, John Radcliffe Hospital, Royal Papworth Hospital NHS Foundation Trust, Divisional patent application, European Innovation Council, Cardiology, Royal Papworth Hospital, European Society of Cardiology, FESC, Nursing, Medical device, MD

SANTA CLARA, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Nick West, MA, MD, FRCP, FESC, FACC, has joined the company in the role of Associate Chief Medical Officer.

Key Points: 
  • SANTA CLARA, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Nick West, MA, MD, FRCP, FESC, FACC, has joined the company in the role of Associate Chief Medical Officer.
  • Dr. West will report to Keith Dawkins, MD, Chief Medical Officer, and will be based in Santa Clara, with plans to succeed Dr. Dawkins as CMO in mid-2024.
  • West brings to Shockwave a wealth of expertise in the interventional cardiology space,” said Dr. Dawkins.
  • He is a founding member and Chief Medical Officer of the Cambridge-based vulnerable plaque startup, PlaqueTec Ltd, and sits on the Innovation Council of the UCLA School of Biodesign.

LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China

Retrieved on: 
Tuesday, September 12, 2023
Research, FDA, Clinical Trials, Cardiology, Other Health, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Mainland China, Week, Cardiovascular disease, FH, CVD, European Society of Cardiology, Placebo, Patient, PCSK9, LIB, ESC, Conference, Therapy, Pharmaceutical industry

LIB Therapeutics Inc. (“LIB”) and Hasten Biopharmaceutical Co., Ltd. (“Hasten”), today announce that the companies have entered into an agreement granting Hasten the rights to develop and commercialize lerodalcibep in Greater China (Chinese Mainland, Hong Kong, Macau and Taiwan).

Key Points: 
  • LIB Therapeutics Inc. (“LIB”) and Hasten Biopharmaceutical Co., Ltd. (“Hasten”), today announce that the companies have entered into an agreement granting Hasten the rights to develop and commercialize lerodalcibep in Greater China (Chinese Mainland, Hong Kong, Macau and Taiwan).
  • LIB is a late-stage, biopharmaceutical company developing lerodalcibep for patients at very high and high-risk of cardiovascular disease (CVD).
  • We look forward to working with LIB to bring lerodalcibep to patients in Greater China as soon as possible.”
    Under the terms of the agreement, LIB has granted Hasten the exclusive rights to develop and commercialize lerodalcibep in Greater China.
  • A joint steering committee will be established to ensure alignment of lerodalcibep’s development in Greater China with LIB’s overall global development and commercialization strategy.